The company said the Growth Portfolio is expected to account for more than 50% of revenues in 2025. It said it introduced Cobenfy, a schizophrenia treatment launched in late October 2024.

8-KRegulation FD DisclosureFiled Jan 13, 2025Period of report Jan 13, 2025Summary published (UTC) Oct 17, 2026

Key points

AI summary

The company said the Growth Portfolio is expected to account for more than 50% of revenues in 2025. It said it introduced Cobenfy, a schizophrenia treatment launched in late October 2024.
The company said it invested about $28B in R&D and about $27B in business development over the 3 years ended September 30, 2024. It said it also returned about $14B to shareholders in dividends and about $16B in share repurchases over the same period.

Summary

AI-written

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call. Some paragraphs were omitted because their support in the source could not be confirmed.

Growth Portfolio share of 2025 revenue

The company said the Growth Portfolio is expected to account for more than 50% of revenues in 2025. It said it introduced Cobenfy, a schizophrenia treatment launched in late October 2024.

Source · Based on the filing body and exhibits

Investment and shareholder returns over the last 3 years

The company said it invested about $28B in R&D and about $27B in business development over the 3 years ended September 30, 2024. It said it also returned about $14B to shareholders in dividends and about $16B in share repurchases over the same period.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.